2024-10-06 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutritional products.

**1. Performance Comparison:**

* **Cumulative Return:** ABT's cumulative return is 100.94% compared to the S&P 500 (VOO) at 131.01%.
* **Performance Gap:** ABT is currently lagging behind VOO by -30.07%. This represents a relative divergence of 12.67% based on historical data, indicating that ABT is performing relatively worse than the S&P 500 over the period considered.

**2. Recent Price Movement:**

* **Closing Price:** $112.23
* **5-day Moving Average:** $113.23
* **20-day Moving Average:** $114.73
* **60-day Moving Average:** $110.65
* **Analysis:** The stock is trading below its 5-day, 20-day, and 60-day moving averages, suggesting a short-term downtrend. 

**3. Technical Indicators:**

* **RSI:** 32.94 (below 50, indicating oversold conditions)
* **PPO:** -0.41 (negative value suggests a bearish trend)
* **Delta_Previous_Relative_Divergence:** -6.9 (negative value suggests a recent short-term decline in relative performance)
* **Expected_Return:** 0.0% (based on current investment and 5-year projection, the expected return is negligible compared to the S&P 500, VOO)

**4. Recent Earnings & Outlook:**

* **Latest Earnings:**
    * Date: 2024-07-31
    * EPS: $0.74
    * Revenue: $10.38 Billion 
* **Analysis:** The company has consistently exceeded revenue expectations over the past few quarters. However, the latest earnings report showed a slight decline in EPS compared to the previous quarter. 
* **Outlook:** Analysts are generally optimistic about the company's long-term growth prospects, citing its strong product pipeline and continued expansion in emerging markets. However, some analysts are concerned about the impact of inflation and potential supply chain disruptions.

**5. News and Recent Issues:**

* **Recent Market Outlook:** The market outlook for ABT is generally positive, driven by its strong brand recognition, diverse product portfolio, and robust financial performance. 
* **Analyst Opinions:** Most analysts rate ABT as a “Buy” or “Hold”, with an average price target of $120 per share.
* **Performance Highlights:** ABT’s strong performance in the medical device segment has been a key driver of growth. The company’s focus on expanding into emerging markets has also contributed to its success.

**6. Overall Analysis:**

ABT currently faces a few challenges, including slower growth in the pharmaceutical segment and potential disruptions in the global supply chain. Despite these factors, the company boasts strong financials, a diversified product portfolio, and a healthy growth outlook. ABT's current position below its moving averages signals a short-term downtrend, but its oversold condition according to the RSI suggests potential for a rebound. While the projected return is currently negligible, the company's long-term growth prospects remain promising.

**7. Recommendation:**

Investors looking for a stable, dividend-paying stock in the healthcare sector may consider ABT. However, investors should monitor the company's performance in the pharmaceutical segment and the global supply chain environment closely. It is advisable to approach this investment with a long-term perspective, taking advantage of potential pullbacks to enter the market. 
